SMARCB1-Deficient Kidney Medullary Carcinoma

SMARCB1-Deficient Kidney Medullary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07438626	Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma	recruiting	Phase 2	20	M.D. Anderson Cancer CenterOTHER	1	Sep 24, 2026	clinicaltrials

Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials